Drug Profile


Alternative Names: PA 824

Latest Information Update: 14 Sep 2016

Price : $50

At a glance

  • Originator Novartis
  • Developer Global Alliance for TB Drug Development
  • Class 2 ring heterocyclic compounds; Antituberculars; Nitroimidazoles; Oxazines; Phenyl ethers; Small molecules
  • Mechanism of Action Cell wall inhibitors; Nitric oxide stimulants; Protein synthesis inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Tuberculosis
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Tuberculosis

Most Recent Events

  • 05 Nov 2015 Medecins Sans Frontieres plans a phase II/III trial for Tuberculosis (Combination therapy) in Uzbekistan and Swaziland (NCT02589782)
  • 01 Mar 2015 Phase-III clinical trials in Tuberculosis (Combination therapy, Treatment-experienced, In adults, In adolescents) in South Africa (PO) (NCT02333799)
  • 15 Jan 2015 Global Alliance for TB Drug Development plans a phase III trial for Tuberculosis (In adults) in multiple countries in Africa, Asia, Eastern Europe and Latin America (NCT02342886)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top